SEC Form 4 · accession 0000899243-16-014616
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Myles Elfont
Officer — Chief Medical Officer
Period of report
Feb 26, 2016
Accepted (ET)
Feb 26, 2016 · 7:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1 | holding | — | — | — | 299,002 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $16.93 | Feb 26, 2016 | A | 80,000 | A | — | Feb 26, 2026 | Common Stock | 80,000 | 80,000 | D |
Explanation of responses
- F1A portion of these shares is subject to a right of repurchase held by the Issuer.
- F2The shares subject to the option will vest and become exercisable as to one-forty-eighth (1/48th) of the total number of shares subject to the option in successive, equal monthly installments measured from February 26, 2016, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.